Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
acknowledged, ADA, adequacy, AE, anaplastic, Anderson, Ansam, assed, assumption, atezolizumab, Atlantic, ATM, avdoralimab, avelumab, awardee, BA, Bangladesh, Belgium, Benchmark, Berlin, BID, Biden, Bio, Biotie, blacklist, breast, bronbelasting, carcinoma, career, carryforward, CDS, Centre, cetuximab, cGCP, chosen, cisplatin, clot, CMC, cobimetinib, collateral, Concession, constitutionality, contractor, Corona, cscc, curable, curative, dehydrogenase, died, distance, distant, dramatically, EGFR, EIR, Eli, endorsed, epidermal, Ernst, exoSTING, feedback, fluidity, foreach, Forest, futility, Georgetown, GlaxoSmithKline, Hospitalier, Imcyse, incl, Indonesia, inflection, interposed, intubated, intubation, invoiced, invoicing, Iveric, Jordan, JP, Kettering, kinase, Korinna, Kuebler, lactate, laherparepvec, Landeskliniken, leakage, lenvatinib, LIBTAYO, Lilly, Lily, LTIP, lymph, lymphocytopenia, MD, Medtronic, Memorial, mepolizumab, MI, Mild, misallocation, monotherapy, NDA, neck, nested, nivolumab, node, Northern, Nucala, obstructive, Oyj, panitumumab, parliament, pattern, paused, PDUFA, PF, Pfizer, photoimmunotherapy, Pilz, platform, Poland, premium, presidential, radiation, Rakuten, ravulizumab, Raymond, reaction, recession, recurrence, recurrent, respiratory, resume, resumed, Salzburger, SAVE, SCC, Scibase, sector, SIC, Sichuan, simplify, solid, Sotio, Southern, SPA, Spain, story, stricter, sun, SVB, Taapken, talimogene, telecommunication, thyroid, tube, turnaround, unavoidable, unbilled, unchanged, upadacitinib, variant, ventilator, Verlustvortrag, vilobelimab, Wagner, Wake, Web, Young, Zhejiang, Zwick
Removed:
Achillion, Arnd, Avery, Biostructure, Cadillac, cancelable, CF, Christ, close, comfort, correspondingly, deed, Dennison, dilutive, dissolution, East, EleGene, excise, excluded, exhibited, exit, Fireman, Frankfurt, indefinitely, leasehold, legally, likewise, loosen, mandate, Moody, notarial, NovImmune, Ophthotech, Poor, Port, Probiodrug, rated, repealing, subscribed, Tabular, tranche, Trump, XBiotech
Filing tables
Filing exhibits
IFRX similar filings
Filing view
External links
Exhibit 15.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors of InflaRx N.V.:
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form F-3 No. 333-239759) of InflaRx N.V. |
(2) | Registration Statement (Form S-8 No. 333-221656) pertaining to the InflaRx N.V. Long-Term Incentive Plan, and |
(3) | Registration Statement (Form S-8 No. 333-240185) pertaining to the InflaRx N.V. Long-Term Incentive Plan, InflaRx Stock Option Plan 2016, InflaRx Options Issued Pursuant To The Series B Financing Arrangement of our report dated March 24, 2021, with respect to the consolidated financial statements of InflaRx N.V. included in this Annual Report (Form 20-F) of InflaRx N.V. for the year ended December 31, 2020. |
/s/ Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft
Munich, Germany
March 25, 2021